

AperTO - Archivio Istituzionale Open Access dell'Università di Torino

Bacterial coinfections in dengue virus disease: what we know and what is still obscure about an emerging concern

This is the author's manuscript

Original Citation:

Availability:

This version is available <http://hdl.handle.net/2318/1741986> since 2020-06-21T20:32:12Z

Published version:

DOI:10.1007/s15010-016-0927-6

Terms of use:

Open Access

Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)

1 **Title Page**

2 **Title:** Bacterial Coinfections in Dengue Virus Disease: What We Know and What Is still Obscure
3 about an Emerging Concern

4 **Authors:** Mattia Trunfio^a, M.D., Alessia Savoldi^b, M.D., Ottavia Viganò^b, M.D, Ph.D., and
5 Antonella d'Arminio Monforte^b, M.D., Ph.D.

6 ^aClinic of Infectious and Tropical Diseases, Amedeo di Savoia hospital, department of Medical
7 Sciences, University of Torino, Torino, Italy. ^aAffiliation address: Clinica Universitaria 1 di Malattie
8 Infettive, Ospedale Amedeo di Savoia, Corso Svizzera 164, 10149, Torino, Italy.

9 ^bClinic of Infectious and Tropical Diseases, San Paolo hospital, department of Health Sciences,
10 University of Milano, Milano, Italy. ^bAffiliation address: Clinica di Malattie Infettive e Tropicali,
11 Ospedale San Paolo, Via A. di Rudinì 8, 20142, Milano, Italy.

12 **Corresponding author:** Mattia Trunfio, M.D. Address: Clinica Universitaria 1 di Malattie Infettive,
13 Ospedale Amedeo di Savoia, Corso Svizzera 164, 10149, Torino, Italy. Phone number:
14 +393383309546; Email: mattia.trunfio@edu.unito.it

15 **Authors email's addresses:** mattia.trunfio@edu.unito.it (Mattia Trunfio), alessia.savoldi@gmail.com
16 (Alessia Savoldi), vigano.ottavia@gmail.com (Ottavia Viganò), antonella.darminio@unimi.it
17 (Antonella d'Arminio Monforte)

18 **Study Sponsorship or Funding source:** none.

19
20
21
22
23
24
25
26

27 **Abstract – 249 words:**

28 **Purpose:** Dengue virus is the most frequent arthropod-borne viral infection worldwide.

29 Simultaneously to the growth of its incidence, cases of bacterial coinfection in dengue have been
30 increasingly reported. The clinical course of dual infections may worsen for reciprocal interactions
31 and delays in the diagnosis, so that clinicians should be aware of this eventuality. Therefore, we
32 reviewed literature to provide an overview of the epidemiological, clinical and physiopathological
33 issues related to bacterial coinfections and bacteremia in dengue.

34 **Methods:** Clinical studies and case reports regarding bacteremia and bacterial coinfections in
35 dengue and the interactions between the pathogens published on PubMed were reviewed.

36 **Results:** We found 26 case reports, only 3 studies on concurrent bacteremia and 12 studies
37 reporting data on bacterial coinfections in dengue. According to the three available studies, the
38 0.18-7% of dengue infections are accompanied by concurrent bacteremia, while the 14.3-44.4% of
39 dengue-related deaths seems associated to bacterial coinfections. Comorbidities, advanced age and
40 more severe dengue manifestations could be risk factors for dual infections. A longer duration of
41 fever and alterations in laboratory parameters such as procalcitonin, hyponatremia, leukocyte count
42 and renal function tests can raise the suspicion.

43 **Conclusions:** Despite the real burden and consequences of this emerging concern is still not
44 computable accurately due to the lack of a significant number of studies on large cohorts, clinicians
45 need a greater awareness about it to early recognize warning signs, to properly use available
46 diagnostic tools and to readily start antibiotic treatment able to prevent worsening in mortality and
47 morbidity.

48 **KeyWords:** Dengue; Bacteremia; Coinfection; Bacteria; Innate Immunity; Pathogenesis.

49 **Acknowledgments:** We are grateful to Irene Molin for the figure and to Ivano Dal Conte for his
50 advices.

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74 **Manuscript – 25.940 characters (including spaces):**

75 **Introduction**

76 *Dengue virus* (DEV) infection is the most frequent arthropod-borne viral disease worldwide,
77 transmitted mainly by *Aedes* spp mosquitoes and caused by one of four different serotypes
78 belonging to the *Flaviviridae* family together with *West Nile virus* and many others. The global
79 burden of DEV has grown dramatically in the last decades and one recent estimate reports 390
80 million of DEV infections per year, of which 96 million clinically manifesting [1]. The clinical
81 presentation of dengue can range from asymptomatic infections to serious life-threatening
82 manifestations such as dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS) [2].
83 The severity of the infection depends on a large number of factors related to the virus and to the
84 host. Moreover, two sequential infections by different serotypes of DEV can predispose to DHF and
85 DSS due to an antibody-dependent enhancement of DEV infection which leads to the generation of
86 a large amount of infected cells [2]. In developed countries the disease is currently sporadic and
87 occurs mainly in travellers, especially those returning from Southeast Asia [3]. It has been estimated
88 that about 2% of all diseases among travellers returning from endemic regions it is caused by DEV
89 [3], but more surveillance data are required to assess the real burden of the disease, especially
90 nowadays considering the increase in intercontinental travels and globalization.

91 There are different reports in literature regarding dual infections with DEV and bacteria such as
92 *Leptospira* spp, *Staphylococcus* spp and *Enterobacteriaceae* [4-6]. Depending on the studies and on
93 the severity of dengue, it seems that from 0.18% to 7% of DEV infections are associated with
94 concurrent bacteremia (CB) [7-9]. Although the overall proportion of dual infections may be small,
95 the absolute number can become awesome considering the above data, especially during major
96 DEV outbreaks. Moreover, the clinical course of dual infections may worsen for dangerous
97 interactions between pathogens, for missed diagnosis due to unusual clinical presentations and for
98 delays in the beginning of the most appropriate therapy, so that clinicians should be aware of this
99 eventuality. It is not clear yet whether and how DEV can predispose to super-infection and to

100 bacteremia. Different hypothesized mechanisms are the induced weakened immunity, the severe
101 neutropenia and the microbial translocation observed during the disease [10-12]. On the other hand,
102 also bacterial infections may increase susceptibility to DEV [13]. To date there is a dearth of studies
103 on this issue, but what seems rational is that concurrent bacterial infections can not always be a
104 mere coincidence. Herein we review the literature about CB and bacterial coinfections in dengue to
105 evaluate the burden of the phenomenon and the possible pathophysiological mechanisms that can
106 explain it and to point out the issues and the limits in managing and in recognition of dual
107 infections.

108 **Materials and Methods**

109 A PubMed search from January 1943, when Kimura and Hotta first isolated DEV, through March
110 2016 was performed to identify case reports and studies addressing the bacterial coinfection and CB
111 issue in DEV infection. We made our search combining *bacteremia*, *coinfection*,
112 *immunosuppression*, *innate immunity*, *case reports* and *bacteria* with *dengue* as Mesh terms and
113 *concurrent bacteremia*, *microbial translocation*, *case report* and *dual infection* with *dengue* as
114 keywords. We considered all case reports with at least an english written abstract. For case reports
115 of which we were not able to read more than the abstract we reported the missing data as not
116 available. Conversely, we considered only english written published or accepted manuscripts of
117 studies on adults and with a bacterial coinfection diagnosis made on the basis of culture tests,
118 considering serological diagnosis of bacterial coinfections unreliable due to cross-reactivity issues,
119 as explained further below. The search was augmented by review of bibliographic references from
120 the included studies and case reports to identify additional relevant papers.

121 Since it is epidemiologically and clinically fundamental to differentiate DEV cases with CB from
122 those with bacterial coinfections without bacteremia or with a positive blood culture collected
123 without stringent temporal limits with respect to dengue diagnosis, data reported by studies that
124 isolated bacteria from blood within a maximum of 72 hours of patient's admission for dengue were
125 considered as data concerning CB, whilst all the studies in which the previous timeframe for blood

126 culture samples collection is missing or exceeded were considered as studies on bacterial
127 coinfections (BC) in dengue. Therefore, BC include also dual infections without bacteremia,
128 infective complications of dengue and nosocomial infections.

129 **Results**

130 We found 26 case reports, 3 studies specifically focused on CB [7-9] and 12 studies [7-9, 11, 14-21]
131 reporting data on CB or BC in DEV disease fulfilling the inclusion criteria. We then summarized
132 the evidences to performe a review of the literature providing an overview of the epidemiological,
133 clinical and physiopathological issues related to BC and CB in DEV infection.

134 **Epidemiological Issues**

135 Only three studies have been addressed to investigate on the CB issue in dengue and they were all
136 retrospective [7-9]. The main characteristics of these studies and of the enrolled populations are
137 summarized in Table 1. The reported CB rates were 0.18% [7], 1.2% [8] and 7% [9]. The first two
138 studies also reported BC rates of 0.3% [7] and 4% [8], which are almost twice and more than triple
139 the CB rates in the same cohorts respectively. Two out of the three studies were conducted on
140 patients presenting a positive laboratory confirmation of DEV infection [7, 8], while Lee et al.
141 evaluated CB in patients affected by DHF or DSS only [9]. This difference may explain the
142 significant gap between the rate they found and those reported by the other two studies. In
143 agreement with the hypothesis that CB and BC rates increase with the increasing severity of DEV
144 infection, as corollary of their main objective, a few studies on smaller cohorts addressing risk
145 factors and outcomes exclusively for DHF reported CB rates similar to those reported by Lee,
146 precisely 7% [14], 7.3% [15] and 8.1% [16]. Solely one out of the three studies on CB in dengue,
147 by Thein et al. [7], has specified that only patients with clinical deterioration despite treatment for
148 DEV were tested with blood cultures, whilst in the other two studies it is not stated whether all the
149 included patients underwent a blood sample collection for bacterial cultures [8, 9]. Therefore, in
150 addition to the limitations related to the retrospective design, it is also possible that some of the dual
151 infection cases were not diagnosed and that the reported rates underestimate the real amount of CB

152 in dengue. To date, only one prospective study has been conducted on bacteremia in dengue, but its
153 aim was not to evaluate CB rates [17]. They examined secondary bacteremia rates in DEV-infected
154 adults with a duration of fever superior to the usual 5 days [17]. They reported a 25% of secondary
155 bacteremia in a small cohort of 40 patients, without providing the timeframe for blood cultures
156 collection and they concluded that an average longer duration of fever respect to the usual lenght of
157 dengue fever could be a warning sign of BC [17]. Actually, considering DEV-infected cohorts
158 selected for specific features, such as the duration of fever or the most severe manifestations of
159 dengue, CB and BC rates may increase, identifying categories of patients at greater risk of dual
160 infections. More specifically, from 26.5% to 45.4% of cases admitted to an intensive care unit for
161 dengue can develop BC [18, 19] and 22.7% of all the admitted cases requires treatment for septic
162 shock [19]. Furthermore, up to 17.4% of elderly patients, i.e. patients with 65 years or more,
163 presenting with DHF may experience CB [15] and the 42.8% of DHF cases who develops acute
164 renal failure has also CB [16]. These data reinforce the hypothesis that CB and BC rates may
165 increase with increasing severity of dengue and that certain categories such as the elderly, the
166 patients requiring intensive care or those developing organ dysfunction could be at greater risk of
167 dual infection during dengue.

168 Among the most frequently isolated bacteria responsible for CB in dengue, as shown in Table 1,
169 there are *Staphylococcus aureus*, *Escherichia coli*, *Klebsiella spp*, *Salmonella spp* and
170 *Streptococcus spp*, while rarely reported are *Pseudomonas aeruginosa*, *Moraxellaceae*,
171 *Enterococcaceae* and *Aeromonas spp* [7-9]. It is interesting to note that a substantial portion of
172 these bacteria are capable of colonizing parts of human body and that when the source of bacterial
173 infection was investigated, no organ localization with primary bacteremia was found to be the most
174 frequent condition. In Table 2 we listed all dual infection case reports found in literature. In case
175 reports a different set of bacteria prevails; the majority of them does not usually colonize human
176 body and it is characterized by peculiar modes of transmission, such as *Mycoplasma pneumoniae* or
177 *Orientia tsutsugamushi*. The difference between the bacterial isolates reported by the previous

178 studies and those reported by case reports may be due at least in part to publication bias and to our
179 inclusion criteria, which are not the same for the two types of scientific report.

180 Although the available reports show that a significant portion of DEV infections could be associated
181 to a bacterial infection, to date there are too few studies on CB and BC in DEV disease to define
182 with certainty the real burden of this emerging concern. Besides, to our knowledge, prospective
183 studies on large sample size of patients are missing and they would help to define more confidently
184 the CB and BC rates in dengue. The available data are also difficult to compare and to analyze
185 together due to the lack of uniformity with which the studies have been conducted and it should be
186 pointed out that all the available informations related to this issue were obtained from cohorts with
187 special features of settings in tropical and subtropical regions [7-9, 14-19] and this may be a
188 limitation to the use of all these data in Western clinicians reality. We need local, national and
189 international surveillance systems for CB and BC in DEV disease and a shared systematic approach
190 to the analysis of the phenomenon. Moreover, we need studies on large cohorts with different
191 features than of those carried out so far, for example studies with a prospective design and with the
192 aim of evaluating the dual infection issue among migrants and travellers in Western countries too.

193 **Clinical Issues**

194 DEV infection fatality rate ranges from 0.5% to 5% and though it may increase twentyfold when
195 DHF and DSS develop, DHF and DSS cases alone account for less than 50% of all DEV-related
196 deaths [14]. Regarding dengue mortality due to CB or BC, the available data are scarce, are
197 provided by a few studies on small cohorts, with just 8-28 fatal cases and a large variability in the
198 reported rates, however, to date what they show is that from 14.3% to 44.4% of DEV-related deaths
199 could be associated to bacterial coinfections [14, 19-21] and that an increased leucocyte count and
200 cell band percentage have been associated with a higher risk of CB and BC and of death in DEV
201 infected patients [14, 19]. If further studies on larger cohorts would confirm the previous rates, the
202 dual infection issue would be certainly not of secondary importance in the management of DEV
203 disease, starting as early as from the triage of patients.

204 A first problem in recognizing dual infections in DEV cases is the perfect overlap of the clinical and
205 laboratory presentation between DEV disease and some of the others infections with which it may
206 present in association. As it is known, most if not all of the signs and symptoms found in DEV
207 disease are not specific [2]. Considering typhoid fever (TF), as example, the diarrhea, the
208 gastrointestinal bleeds, the singular pattern of increase in transaminases for which AST level rises
209 more quickly and reaches a higher value than ALT and then reverts to normality first, the leukopenia
210 with neutropenia, the thrombocytopenia and even the relative bradycardia may all be found also in
211 DEV infection [2, 22-24].

212 Few studies have attempted to describe how DEV clinical presentation changes in conjunction with
213 bacterial infections and what are the risk factors for CB. The first study was conducted by Lee et al.
214 [9] on adults with DHF and DSS only. Patients with dual infections were older, with a longer
215 lasting fever (an average of 8 vs 4 days) and with higher frequencies of DSS, acute renal failure,
216 gastrointestinal bleed, altered consciousness, unusual DEV manifestations and mortality [9]. Acute
217 renal failure and a fever lasting for more than 5 days were found to be independent risk factors for
218 CB [9]. These conclusions agree with the previously reported studies on DEV-infected patients with
219 a long lasting fever or developing acute renal failure, in whom dual infection rates were higher
220 compared to those found in patients without these complications [16, 17].

221 See et al. found that patients with DEV and CB were more likely to have several comorbidities, in
222 particular diabetes mellitus, hypertension, hyperlipidemia, chronic renal failure and cancer and that
223 they have a higher hospital mortality [8]. Besides, they created and validated a Dengue Dual
224 Infection Score (DDIS) for early identification of DEV infected patients in need of empirical
225 antibiotic treatment [8]. The DDIS can range from 0 to 5 and it is obtained from the attribution of
226 one point for each of the following parameters if present within 24 hours from admission: pulse rate
227 ≥ 90 beats/min, total white cell count $\geq 6.000/\mu\text{L}$, hematocrit $< 40\%$, sodium < 135 mmol/L and
228 urea ≥ 5 mmol/L [8]; a *DDIS* ≥ 4 was found to be associated to CB in 94.4% of cases [8]. It is
229 interesting to note that the same cut-off of 6.000 white blood cells has been associated with a higher

230 risk of BC and with a risk of death increased by almost 10 times [19]. Moreover, studies on severe
231 DEV infections identified in the increased leukocyte and cell band count a significant warning sign
232 of serious dengue, suggesting the possibility of a superimposing bacterial infection [14, 19]. Lastly,
233 Thein et al. compared CB cases with only DEV-infected cases and found that at admission dual
234 infected patients have higher mean temperatures (38.4°C vs 37.6°C) and neutrophil count, more
235 frequently a Pitt Bacteremia Score (PBS) ≥ 4 , hematocrit change $\geq 20\%$ and DSS, while they have
236 lower serum albumin levels, lymphocyte and platelet count and surprisingly lower rates of
237 hemorrhagic manifestations [7]. DEV-infected patients with CB need also more volume of fluids
238 for a longer period [7]. They concluded proposing the PBS as a valuable resource to detect early CB
239 in DEV infections, but not all the dual infections evolve in severe sepsis and even less start so
240 severely, while PBS only distinguishes between patients critically ill or not [7].

241 A promising contribution to identify BC and CB among patients with confirmed DEV infection
242 could come from the use of procalcitonin. Currently only one study investigated on that and it was
243 carried out on patients admitted to intensive care unit for dengue [18]. The patients with bacteremia
244 showed significantly higher procalcitonin level than those without, so that they suggested that
245 procalcitonin assessment could help to exclude bacteremia in DEV cases, considering its high
246 sensitivity and negative predictive value [18].

247 Once the dual infection is suspected, it is fundamental to use the correct diagnostic tools to confirm
248 the suspicion. Depending on the available DEV serology test, sensitivity and specificity can range
249 considerably and false positivity for DEV in case of leptospirosis, brucellosis and TF has been
250 described, probably due to polyclonal activation or cross-reactivity occurrence [25, 26]. Moreover,
251 it is possible also the contrary. For example, the Widal serodiagnosis used to detect *Salmonella*
252 *typhi* may result falsely positive in patients affected by DEV [27]. As shown in Table 2, a large part
253 of dual infections is diagnosed by physicians using only DEV serology. Cases considered as
254 coinfections may actually be a single infection with a false positive serology for one of the two
255 implicated pathogens and solely a positive bacterial culture associated with a direct diagnostic

256 method for DEV, such as PCR or NS1 antigen detection, would give the certainty of the dual
257 infection.

258 **Physiopathological Issues**

259 DEV pathogenic mechanisms have been investigated in detail, but little is known about the
260 pathogenesis of BC and CB in dengue. The majority of case reports and studies [4-9, 17] cite as the
261 possible cause of this clinical concern the vascular leakage and the associated disintegration of the
262 mucocutaneous barrier described during dengue [5, 12, 28, 29]. Consistent with this hypothesis are
263 the previously reported data on bacterial isolates from DEV-infected patients which show that a
264 large portion of the bacteria involved in coinfection are usual colonizing of human body [7-9].
265 Considering that one of the main DEV cellular target are monocytes/macrophages and that a large
266 number of these cells resides in the gut [28], the replication of DEV in them may produce an
267 inflammatory milieu, where the breakdown of the digestive epithelial barrier occurs [12, 28, 29],
268 followed by the microbial translocation (MT) of resident bacteria from the enteric lumen into the
269 bloodstream [12, 28, 29]. The same event has been hypothesized also for *Staphylococcal*
270 bacteremia, following disruption of the cutaneous endothelial lining in patients with predisposing
271 skin comorbidities and dengue [5]. Recent studies reported higher plasma levels of microbial
272 translocation markers in DEV infected patients compared to healthy controls [28]. It also seems that
273 MT correlates with DEV infection severity [12, 28]. However, this pathogenic model has yet to be
274 demonstrated in vivo. If we consider the MT as the only mechanism whereby explaining dual
275 infections, we should expect a higher incidence of bacterial infections in patients with greater
276 vascular damage and hemorrhagic signs, but evidences are still conflicting. If CB and BC rates
277 seem to increase with increasing severity of DEV and coinfecting patients seem to develop more
278 frequently DSS [7], it is also true that lower rates of hemorrhagic manifestations has been noted in
279 dual infections compared to only DEV-infected controls [7]. Finally, the MT model cannot explain
280 all bacterial coinfections in dengue. For instance, especially in high-incidence countries for TF, an
281 undetermined number of chronic carriers of *Salmonella typhi* could face *Salmonella typhi*

282 bacteremia if infected by DEV through MT, but *Salmonella* spp and some of the other bacteria
283 involved in dual infections, such as *Leptospira* spp, don not usually represent part of the normal
284 flora of the gut, protagonist of MT. Furthermore, it should be state that some of the reported
285 coinfections such as those with *Leptospirosis* spp, *Burkholderia pseudomallei*, *Mycoplasma*
286 *pneumoniae* or *Orientia tsutsugamushi* could merely be a co-occurrence by chance of both the
287 pathogens in the same individual.

288 Hypothetically, another possible mechanism to explain bacterial coinfections might be the severe
289 absolute neutropenia, which may develop due to bone marrow suppression induced by DEV [11].
290 Despite this hypotesis could be reasonable, in a retrospecitve study on a large cohort of DEV-
291 infected patients, a neutrophil count ≤ 500 cells/ μ L was not found to be a predictor of nosocomial
292 bacterial infections nor it was associated with a more frequent antibiotic use, probably because of
293 the short and transient duration of the neutropenia [11].

294 It seems that DEV can cause a transitory immune suppression affecting the immune system cells
295 during acute infection [10], so much so that during and after the infection immune system is less
296 effective in mounting a defensive response also against secondary bacterial threats. In fact, DEV
297 seems able to diminish response to proliferative stimuli in T cell populations by impairing antigen-
298 presenting cells functions [30], to reduce the phagocitic and migratory skills of splenic and
299 peritoneal-cavity macrophages [31] and to suppress the interferon signaling pathway through the
300 down-regulation of different genes [32]. Moreover, in mosquitoes DEV seems capable of increasing
301 the susceptibility to *Staphylococcus aureus* and *Pseudomonas aeruginosa* septic injury [33] and of
302 down-regulating the expression of different genes involved in the major innate immunity pathways,
303 including some genes coding for receptors of viral and bacterial pathogen-associated molecular
304 patterns and for antimicrobial peptides, the production of which was shown to be reduced in
305 response to bacterial challenges [34]. Considering the notable overlap between the innate immune
306 system of diptera and human [33, 34], the explanation of bacterial and DEV coinfections may be
307 found by studies on interactions between DEV and the human innate immune systems. Actually, in

308 human myeloid/plasmocytoid dendritic cells and monocytes DEV can affect the expression of some
309 co-stimulatory molecules and of the Toll-Like Receptors (TLRs), proteins with a pivotal role in the
310 innate immune system [35]. The modulation of the expression of TLRs may influence not only the
311 development of a specific immune response against the virus, but also the dendritic cells activation
312 [35], thereby influencing immune responses involved in antibacterial defenses as well. This effect
313 seems to depend on the severity of DEV infection [35] and consistent with these findings, the
314 presence of subneutralizing antibodies induced by previous exposure to a different DEV serotype
315 has been linked not only to a higher risk of severe form of dengue, but also to a more prominent
316 down-regulation of TLRs expression and up-regulation of suppressors of the NF- κ B signaling
317 pathway, crucial for cytokine production [36]. Considering these results, the aforementioned higher
318 CB and BC rates in DHF and DSS cases should not surprise. A summary of the main mechanisms
319 through which DEV may induce CB and BC is represented in Figure 1.

320 Finally, if it is possible that DEV can facilitate CB and BC, it is also possible that bacterial
321 contagion could increase susceptibility to more symptomatic and severe forms of dengue. It has
322 been described a modulating effect of LPS, the Gram-negative outer membrane endotoxin, on DEV
323 replication [13]. Chen et al. observed that when LPS was added to in vitro cultures of human
324 monocytes and macrophages after DEV infection, DEV replication was enhanced and prolonged
325 [13] and similar conclusions were also reached by one study in *Aedes aegypti* cells cultures [34].
326 These findings are strongly suggestive of a modulation over the viral load and the immune response
327 carried out by concurrent Gram-negative coinfections during dengue, they seem to agree with the
328 previously cited study reporting a correlation between dengue severity and LPS plasma levels [28]
329 and if they were confirmed in human models, we could even expect that in Gram-negative
330 coinfections signs and symptoms related to DEV active replication could temporarily worsen or be
331 prolonged right after the beginning of the antibiotic therapy because of the release of a large amount
332 of LPS from killed bacteria.

333 We are clearly far from understanding the physiopathology of CB and BC in dengue, but certainly
334 we can note that there is a mutual life-threatening strengthening influence between DEV and
335 bacteria.

336 **Conclusion**

337 A significant portion of dengue cases could be associated to a bacterial infection, but the real
338 burden of this emerging concern is still not computable accurately due to the lack of a shared
339 approach to the study of this issue and of a surveillance system monitoring and reporting
340 systematically the dual infections, also in western countries. Clinicians need a greater awareness
341 about CB and BC in dengue since that in addition to be potentially more serious and with a higher
342 risk of complications, dual infections can put clinicians in front of management problems and can
343 predispose to delays in the diagnosis and in the beginning of the most appropriate therapy, able to
344 prevent aggravation in mortality and morbidity. We encourage clinicians to suspect CB and BC in
345 any DEV case, especially in patients with comorbidities, elderly, with a long lasting fever or more
346 severe forms of dengue. In such cases, the DDIS and the procalcitonin may prove useful diagnostic
347 tools, if their high specificity and sensitivity respectively will be confirmed by further studies [8,
348 18]. Moreover, not to prescribe unnecessary antibiotics because of false positive results, when it is
349 possible, we recommend to prefer biological sample culture tests over serology to confirm a
350 suspicion of bacterial coinfection in dengue, considering yet that some of the involved
351 microorganisms could be difficult to culture. Nevertheless, we do not recommend the indiscriminate
352 use of biological sample cultures nor the administration of an empiric antibiotic treatment to each
353 suspected or confirmed DEV case, since that the former would result in a huge waste of human and
354 economic resources, especially in developing countries and the latter may lead to the selection of
355 multiresistant bacteria. Evaluating the risk factors, the laboratory, the clinical presentation and its
356 evolution, clinicians should be able to identify DEV-infected patients in need of appropriate further
357 diagnostic investigations and of an empiric antibiotic therapy to reduce mortality and morbidity.

358 **Conflict of Interest:** The authors have no conflict of interest to declare.

359 **Fig. 1** The hypothesized mechanisms whereby *Dengue Virus* may induce Concurrent Bacteremia and
 360 Bacterial Coinfections

361 **References:**

- 362 1. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, et al. The global distribution and burden
 363 of dengue. *Nature*. 2013 Apr 25;496(7446):504-7.
- 364 2. Simmons CP, Farrar JJ, Nguyen vV, Wills B. Dengue. *N Engl J Med*. 2012 Apr 12;366(15):1423-32.
- 365 3. Wilder-Smith A. Dengue infections in travellers. *Paediatr Int Child Health*. 2012 May; 32(s1): 28–32.
- 366 4. Pèrez Rodríguez NM, Galloway R, Blau DM, Traxler R, Bhatnagar J, Zaki SR, et al. Case series of fatal
 367 *Leptospira* spp./dengue virus co-infections-Puerto Rico, 2010-2012. *Am J Trop Med Hyg*. 2014 Oct;
 368 91(4):760-5.
- 369 5. Chai LY, Lim PL, Lee CC, Hsu LY, Teoh YL, Lye DC, et al. Cluster of *Staphylococcus aureus* and Dengue
 370 Co-infection in Singapore. *Ann Acad Med Singapore*. 2007 Oct;36(10):847-50
- 371 6. Srinivasaraghavan R, Narayanan P, Kanimozhi T. Culture proven *Salmonella typhi* co-infection in a child with
 372 dengue fever: a case report. *J Infect Dev Ctries*. 2015 Sep 27; 9(9): 1033-5.
- 373 7. Thein TL, Ng EL, Yeang MS, Leo YS, Lye DC. Risk factors for concurrent bacteremia in adult patients with
 374 dengue. *J Microbiol Immunol Infect*. 2015 Aug 4; doi: 10.1016/j.jmii.2015.06.008
- 375 8. See KC, Phua J, Yip HS, Yeo LL, Lim TK. Identification of concurrent bacterial infection in adult patients
 376 with Dengue. *Am J Trop Med Hyg*. 2013 Oct;89(4):804-10.
- 377 9. Lee IK, Liu JW, Yang KD. Clinical characteristics and risk factors for concurrent bacteremia in adults with
 378 dengue hemorrhagic fevers. *Am J Trop Med Hyg*. 2005 Feb;72(2):221-6.
- 379 10. Green AM, Beatty PR, Hadjilaou A, Harris E. Innate immunity to dengue virus infection and subversion of
 380 antiviral responses. *J Mol Biol*. 2014 March 20; 426(6): 1148–1160.
- 381 11. Thein TL, Lye DC, Leo YS, Wong JGX, Hao Y, Wilder-Smith A. Short report: severe neutropenia in dengue
 382 patients: prevalence and significance. *Am J Trop Med Hyg*. 2014 Jun;90(6):984-7.
- 383 12. Van de Weg CAM, Pannuti CS, de Araújo ESA, van den Ham HJ, Andeweg AC, Boas LS, et al. Microbial
 384 translocation is associated with extensive immune activation in dengue virus infected patients with severe
 385 disease. *PLoS Negl Trop Dis*. 2013 May 23;7(5): e2236.
- 386 13. Chen YC, Wang SY. Activation of terminally differentiated human monocytes/macrophages by dengue virus:
 387 productive infection, hierarchical production of innate cytokines and chemokines, and the synergistic effect of
 388 lipopolysaccharide. *J Virol*. 2002 Oct;76(19):9877-87.

- 389 14. Lee IK, Liu JW, Yang KD. Fatal dengue hemorrhagic fever in adults: emphasizing the evolutionary pre-fatal
390 clinical and laboratory manifestations. *PLoS Negl Trop Dis.* 2012;6(2); doi: 10.1371/journal.pntd.0001532
- 391 15. Lee IK, Liu JW, Yang KD. Clinical and laboratory characteristics and risk factors for fatality in elderly
392 patients with dengue hemorrhagic fever. *Am J Trop Med Hyg.* 2008 Aug;79(2):149-53
- 393 16. Lee IK, Liu JW, Yang KD. Clinical characteristics, risk factors, and outcomes in adults experiencing dengue
394 hemorrhagic fever complicated with acute renal failure. *Am J Trop Med Hyg.* 2009 Apr;80(4):651-5.
- 395 17. Premaratna R, Dissanayake D, Silva FHDS, Dassanayake M, de Silva HJ. Secondary bacteraemia in adult
396 patients with prolonged dengue fever. *Ceylon Med J.* 2015 Mar;60(1):10-2.
- 397 18. Chen CM, Chan KS, Chao HC, Lai CC. Diagnostic performance of procalcitonin for bacteremia in patients
398 with severe dengue infection in the intensive care unit. *J Infect.* 2016 Mar 28; doi:
399 10.1016/j.jinf.2016.03.013.
- 400 19. Amâncio FF, Heringer TP, de Oliveira Cda C, Fassy LB, de Carvalho FB, Oliveira DP et al. Clinical Profiles
401 and Factors Associated with Death in Adults with Dengue Admitted to Intensive Care Units, Minas Gerais,
402 Brazil. *PLoS One.* 2015 Jun 19;10(6):e0129046.
- 403 20. Leo YS, Thein TL, Fisher DA, Low JG, Oh HM, Narayanan RL, et al. Confirmed adult dengue deaths in
404 Singapore: 5-year multi-center retrospective study. *BMC Infect Dis.* 2011 May 12;11:123
- 405 21. Lahiri M, Fisher D, Tambyah P. Dengue mortality: reassessing the risks in transition countries. *Trans R Soc*
406 *Trop Med Hyg.* 2008 Oct;102(10):1011-6.
- 407 22. Trung DT, Thao LTT, Hien TT, Hung NT, Vinh NN, Hien PT, et al. Liver involvement associated with dengue
408 infection in adults in vietnam. *Am J Trop Med Hyg.* 2010 Oct;83(4):774-80.
- 409 23. Parry CM, Hien TT, Dougan G, White NJ, Ferrar JJ. Typhoid Fever. *N Engl J Med.* 2002 Nov
410 28;347(22):1770-82.
- 411 24. Lateef A, Fisher DA, Tambyah PA. Dengue and Relative Bradycardia. *Emerg Infect Dis.* 2007 Apr; 13(4):
412 650–651.
- 413 25. Lam SK, Devine PL. Evaluation of capture ELISA and rapid immunochromatographic test for the
414 determination of IgM and IgG antibodies produced during dengue infection. *Clin Diagn Virol.* 1998 May
415 1;10(1):75-81.
- 416 26. Bzeizi KI, Benmoussa A, Sanai FM. Coincidence of Acute Brucella Hepatitis and Dengue Fever or Serologic
417 Cross-reactivity?. *Saudi J Gastroenterol.* 2010 Oct; 16(4): 299–301
- 418 27. Olopoenia LA, King AL. Widal agglutination test-100 years later: still plagued by controversy. *Postgrad Med*
419 *J.* 2000 Feb;76(892):80-4.

- 420 28. Van de Weg CA, Koraka P, van Gorp EC, Mairuhu AT, Supriatna M, Soemantri A, van de Vijver DA, et al.
421 Lipopolysaccharide levels are elevated in dengue virus infected patients and correlate with disease severity. *J*
422 *Clin Vir*. 2012 Jan;53(1):38-42.
- 423 29. Lin CF, Lei HY, Shiau AL, Liu CC, Liu HS, Yeh TM, et al. Antibodies from dengue patient sera cross-react
424 with endothelial cells and induce damage. *J Med Vir*. 2003 Jan;69(1):82-90.
- 425 30. Mathew A, Kurane I, Green S, Vaughn DW, Kalajanoorj S, Suntayakorn S, et al. Impaired T cell proliferation
426 in acute dengue infection. *J Immunol*. 1999 May 1;162(9):5609-15.
- 427 31. Gulati L, Chaturvedi UC, Mathur A. Depressed macrophage functions in dengue virus-infected mice: role of
428 the cytotoxic factor. *Br J Exp Path*. 1982 Apr;63(2):194-202.
- 429 32. Munoz-Jordan JL, Sanchez-Burgos GG, Laurent-Rolle M, Garcia-Sastre A. Inhibition of interferon signaling
430 by dengue virus. *Proc Natl Acad Sci USA*. 2003 Nov 25;100(24):14333-8
- 431 33. Querenet M, Danjoy M-L, Mollereau B, Davoust N. Expression of dengue virus NS3 protein in *Drosophila*
432 alters its susceptibility to infection. *Fly (Austin)*. 2015 Jan 2;9(1):1-6.
- 433 34. Sim S, Dimopoulos G. Dengue Virus inhibits immune responses in *Aedes aegypti* cells. *PLoS ONE*. 2010 May
434 18;5(5):e10678.
- 435 35. Torres S, Hernández JC, Giraldo D, Arboleda M, Rojas M, Smit JM, Urcuqui-Inchima S. Differential
436 expression of Toll-like receptors in dendritic cells of patients with dengue during early and late acute phases of
437 the disease. *PLoS Negl Trop Dis*. 2013;7(2):e2060.
- 438 36. Modhiran N, Kalayanaroorj S, Ubol S. Subversion of innate defenses by the interplay between DENV and pre-
439 existing enhancing antibodies: TLRs signaling collapse. *PLoS Negl Trop Dis*. 2010 Dec 21;4(12):e924.
- 440
441
442
443
444
445
446
447
448
449
450

451 Table 1. Main features of the three published studies focused on Concurrent Bacteremia in Dengue

	Lee IK et al, Am J Trop Med Hyg 2005	See KC et al, Am J Trop Med Hyg 2013	Thein TL et al, J Microbiol Immunol Infect 2015
Study population	100	2065	9553
Study design	Retrospective	Retrospective	Retrospective
Age	>18 years	>16 years	>18 years
Female	46 (46%)	860 (42%)	NA
Country	Taiwan	Singapore	Singapore
DEV cases	DHF or DSS	All types	All types
CB	7 (7%)	25 (1,2%)	18 (0,18%)
BC	NA	83 (4%)	29 (0,3%)
Fatality rate	2/7 (28,5%)	16/83 (19,3%)	3/18 (16,7%)
Source of Bacteremia	1 Meningitis 1 Facial cellulitis 5 Primary bacteremia	3 Endocarditis 2 Vascular infections 1 Limb cellulitis 6 Bile ducts infections 4 UTI 9 Primary bacteremia	NA
Isolated Pathogens	3 <i>Klebsiella pneumoniae</i> 1 <i>Klebsiella ozaenae</i> 1 <i>Roseomonas</i> spp 1 <i>Moraxella lacunata</i> 1 <i>Enterococcus faecalis</i>	8 <i>Staphylococcus aureus</i> (5 MSSA and 3 MRSA) 6 <i>Escherichia coli</i> 4 <i>Klebsiella pneumoniae</i> 2 <i>Salmonella typhi</i> 1 <i>Salmonella enteritidis</i> 1 <i>Streptococcus agalactiae</i> 1 <i>Group A streptococcus</i> 1 <i>Aeromonas maltophilia</i> 1 <i>Kluyvera cryocrescens</i>	5 <i>Staphylococcus aureus</i> 4 <i>Salmonella typhi</i> 3 <i>Escherichia coli</i> 2 <i>Klebsiella pneumoniae</i> 2 <i>Streptococcus</i> spp 1 <i>Pseudomonas aeruginosa</i> 1 Unspecified anaerobe

CB Diagnosis	Any positive blood culture within 72 hours of admission for DEV	Any positive blood culture within 48 hours of admission for DEV or Any clinical diagnosis	Any positive blood culture within 72 hours of admission for DEV
Blood Culture testing Criteria	NA	NA	Patients presenting clinical deterioration despite DEV treatment
DEV Diagnosis	PCR, IgM capture ELISA or fourfold increase of HIT	PCR, IgM ELISA or NS1 antigen	RT-PCR or Rapid Dengue Duo Strip Test
Exclusion Criteria	Prior antibiotic treatment Contamination of cultures	Contamination of cultures	NA

452 Legend: DHF Dengue Hemorrhagic Fever; DSS Dengue Shock Syndrome; CB Concurrent Bacteremia; BC Bacterial
453 Coinfections including also CB; NA Not Available for missing or unspecified data; UTI Urinary Tract Infections;
454 MSSA Methicillin-Sensitive *Staphylococcus aureus*; MRSA Methicillin-Resistant *Staphylococcus aureus*; HIT
455 Hemagglutination inhibition titers; RT-PCR Reverse Transcriptase-Polymerase Chain Reaction.

456

457

458

459

460

461

462

463

464

465

466 Table 2. Bacterial Coinfections and Concurrent Bacteremia in Dengue: case reports from literature

Age & Sex	Associated Bacteria	Diagnostic tests	Possible DB	Outcome	Reference
NA	<i>Salmonella typhi</i>	NA	No	Recovery	Bansal R et al, Trop Doct 2015
10 F	<i>Leptospira</i> spp	DEV and <i>Leptospira</i> IgM serology	Yes	Recovery	Nunez-Garbin A et al, Rev Peru Med Exp Salud Publica 2015
52 M	<i>Leptospira</i> spp	DEV and <i>Leptospira</i> serology	Yes	Death	Wijesinghe A et al, BMC Res Notes 2015
10 M	<i>Salmonella typhi</i>	Blood cultures for <i>S typhi</i> , DEV NS1 and IgM ELISA	No	Recovery	6
22, 64, 67 M	<i>Leptospira</i> spp	<i>Leptospira</i> spp antigen, IHC and PCR on autoptic samples, DEV RT-PCR	No	Death	4
25 F	<i>Orientia tsutsugamushi</i>	Weil-Felix and PCR for <i>O tsutsugamushi</i> , DEV NS1 and IgM	No	Recovery	Kumar S et al, J Vector Borne Dis 2014
30 F	<i>Stenotrophomonas maltophilia</i>	Blood culture for <i>S maltophilia</i> , DEV NS1 antigen	No	Recovery	Sriranaraj S et al, Australas Med J 2014
48 F	<i>Enterococcus faecium</i>	Blood cultures for <i>E faecium</i> , DEV IgG serology	Yes	Death	Tsai JJ et al, Southeast Asian J Trop Med Public Health 2013
24 M	<i>Salmonella typhi</i>	Blood cultures for <i>S typhi</i> , DEV NS1 and serology	No	Recovery	Vaddadi S et al, Int J Res Dev Health 2013

17 M	<i>MRSA</i>	Blood culture for <i>MRSA</i> , DEV IgM ELISA	Yes	Death	Sunderalingam V et al, Case Rep Infect Dis 2013
42 M	<i>Leptospira</i> spp	<i>Leptospira</i> spp antigen IHC on kidney autoptic samples, DEV NS1 on blood	No	Death	Sharp TM et al, Emerg Infect Dis 2012
46 NA	<i>Leptospira</i> spp	NA	No	NA	Cadelis G, Rev Pneumol Clin 2012
40 F	<i>Orientia tsutsugamushi</i>	Weil-Felix and IgM for <i>O tsutsugamushi</i> , DEV IgM	Yes	Recovery	Iqbal N et al, Trop Med Health 2012
15 M	<i>Staphylococcus aureus</i>	Sputum cultures for <i>S aureus</i> , DEV ELISA serology	Yes	Recovery	Nagassar RP et al, BMJ Case Rep 2012
28 M	<i>Burkholderia pseudomallei</i>	Ascitic fluid culture for <i>B pseudomallei</i> , DEV PCR on autoptic samples	No	Death	Macedo RN et al, Rev Soc Bras Med Trop 2012
14 M	<i>Staphylococcus aureus</i>	Autoptic samples cultures for <i>S aureus</i> , DEV IHC on autoptic samples	No	Death	Araujo SA et al, Am J Trop Med Hyg 2010
23 M	<i>Brucella melitensis</i>	Blood culture for <i>B melitensis</i> , DEV serology	Yes	Recovery	26
23 M	<i>Leptospira</i> spp	<i>Leptospira</i> and DEV IgM ELISA	Yes	Recovery	Behera B et al, J Infect Dev Ctries 2009
36, 39, 39, 42, 43 M	<i>Staphylococcus aureus</i>	Blood, intraoperative and wound specimens cultures for <i>S aureus</i> , DEV PCR on serum	No	Recovery	5

6 F	<i>Streptococcus pyogenes</i>	Blood cultures for <i>S pyogenes</i> , DEV serology	Yes	Recovery	Vitug MR et al, Int J Dermatol 2006
8 F	<i>Mycoplasma pneumoniae</i>	<i>Mycoplasma</i> agglutination test, DEV IgM rapid test, RT- PCR and hemoagglutination test	Yes	Recovery	Likitnukul S et al, Southeast Asian J Trop Med Public Health 2004
6, 9 F, 9, 11 M	<i>Salmonella typhi</i> <i>Salmonella paratyphi</i>	Blood cultures for <i>Salmonella</i> spp, DEV IgM rapid test and hemagglutination test	Yes	Recovery	Basuki PS, Folia Med Indon 2003
44 F	<i>Shigella sonnei</i>	Stool culture for <i>S sonnei</i> , DEV IgM rapid test and Duo IgM IgG-capture ELISA	Yes	Recovery	Charrel RN et al, Emerg Infect Dis 2003
NA	<i>Leptospira</i> spp	NA	No	NA	Kaur H et al, Indian J Gastroenterol 2002
2 F	<i>Leptospira</i> spp	<i>Leptospira</i> and DEV IgM ELISA	Yes	Recovery	Rele MC et al, Indian J Med Microbiol 2001
19 F, 32 M	<i>Salmonella typhi</i>	Blood cultures for <i>S typhi</i> , DEV serology	No	Recovery	Sudjana P et al, Southeast Asian J Trop Med Public Health 1998


467 Legend: DB Diagnostic Bias; DEV *Dengue virus*; NA Data Not Available; IHC Immunohistochemistry; MRSA
468 Methicillin-resistant *Staphylococcus aureus*; RT-PCR Reverse-Transcriptase Polymerase Chain Reaction.

469

470

471

472 Figure 1 The hypothesized mechanisms whereby dengue virus may induce concurrent bacteremia
473 and bacterial coinfections



474